Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

39.98
+1.012.59%
Volume:77.04K
Turnover:3.05M
Market Cap:3.75B
PE:-6.36
High:40.07
Open:39.20
Low:39.20
Close:38.97
Loading ...

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y

Zacks
·
14 Feb

Wedbush Sticks to Their Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
14 Feb

Morgan Stanley Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
14 Feb

Ultragenyx Pharma Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Feb

Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating

TIPRANKS
·
14 Feb

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

GuruFocus.com
·
14 Feb

U.S. RESEARCH ROUNDUP-Airbnb, CVS Health, Roku

Reuters
·
14 Feb

Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating

TIPRANKS
·
14 Feb

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
14 Feb

Ultragenyx Pharmaceutical Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
14 Feb

Ultragenyx: Q4 Earnings Snapshot

Associated Press Finance
·
14 Feb

Ultragenyx Pharmaceutical Inc - 2025 Financial Guidance: Total Revenue Between $640 Million to $670 Million

THOMSON REUTERS
·
14 Feb

Ultragenyx Pharmaceutical Q4 2024 GAAP EPS $(1.39) Misses $(1.29) Estimate, Sales $164.877 Miss $155.393M Estimate

Benzinga
·
14 Feb

BRIEF-Ultragenyx Q4 EPS USD -1.39 Vs. IBES Estimate USD -1.29

Reuters
·
14 Feb

Ultragenyx Q4 Operating Expenses USD 287 Million

THOMSON REUTERS
·
14 Feb

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

GlobeNewswire
·
14 Feb

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

GlobeNewswire
·
13 Feb

Frank Sands Reduces Stake in Ultragenyx Pharmaceutical Inc.

GuruFocus
·
13 Feb

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

GlobeNewswire
·
07 Feb